Press Releases
Search
-
04 May 2020
BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Us...
-
16 Apr 2020
First-Quarter 2020 Business Review
bioMérieux fully mobilized against COVID-19 epidemic Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter: €769 million in sales Up 21.5% as rep...
-
09 Apr 2020
bioMérieux’s Annual General Meeting postponed
Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on...
-
24 Mar 2020
bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration...
-
11 Mar 2020
First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux
bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physician...
-
26 Feb 2020
2019 Financial Results
€2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sale...